Free Trial
NASDAQ:XBIO

Xenetic Biosciences Q1 2024 Earnings Report

Xenetic Biosciences logo
$2.89 +0.07 (+2.34%)
Closing price 08/22/2025 03:19 PM Eastern
Extended Trading
$2.91 +0.02 (+0.83%)
As of 08/22/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xenetic Biosciences EPS Results

Actual EPS
-$0.78
Consensus EPS
-$0.79
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Xenetic Biosciences Revenue Results

Actual Revenue
$0.51 million
Expected Revenue
$0.65 million
Beat/Miss
Missed by -$140.00 thousand
YoY Revenue Growth
N/A

Xenetic Biosciences Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Friday, May 10, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Xenetic Biosciences' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Wednesday, November 12, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Xenetic Biosciences Earnings Headlines

Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update
HC Wainwright Issues Positive Estimate for XBIO Earnings
The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”tc pixel
Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright
See More Xenetic Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email.

About Xenetic Biosciences

Xenetic Biosciences (NASDAQ:XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

View Xenetic Biosciences Profile

More Earnings Resources from MarketBeat